Abstract:
Objective To retrospectively study the efficacy and safety of adriamycin ifosfamide (AI) combined with anlotinib maintenance therapy in patients with lung metastasis of soft tissue sarcoma.
Methods Patients with lung metastasis of soft tissue sarcoma treated in the tumor hospital of Tianjin Medical University from June 2018 to April 2022 were collected. They received AI and anlotinib maintenance treatment. The treatment effect was evaluated according to the solid tumor efficacy evaluation standard (RECIST) 1.1, the objective response rate (ORR) and disease control rate (DCR) were calculated, and the median progression-free survival (mPFS), median overall survival (mOS) and related adverse events were statistically analyzed.
Results A total of 32 patients with lung metastasis of soft tissue sarcoma were included. One patient achieved complete response (CR) (3.1%), and 10 had partial response (PR) (31.2%), 9 had stable disease (SD) (28.1%), 12 had progress disease (PD) (37.5%); ORR was 34.3%, DCR was 62.5%. The mPFS was 6.0 months and mOS was 15.0 months. The treatment-related adverse events of most patients were grade 1-2. Grade 3-4 adverse events included pleural effusion (n=2, 6.25%), anemia (n=5, 15.6%), leucopenia (n=4, 12.5%). Grade 5 adverse events were pneumothorax (n=1, 3.1%).
Conclusions AI combined with anlotinib maintenance therapy has a certain effect on patients with lung metastasis of soft tissue sarcoma. Most patients can tolerate the adverse events, which can be used as an effective treatment for lung metastasis of soft tissue sarcoma.